Citigroup
INO icon

Citigroup’s Inovio Pharmaceuticals INO Stock Holding History

Citigroup’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,977
Closed -$30.4K – 6248
2025
Q3 		$30.4K Sell
12,977
-1,645
-11% -$3.15K ﹤0.01% 4657
2025
Q2 		$29.8K Sell
14,622
-10,420
-42% -$20K ﹤0.01% 4976
2025
Q1 		$40.8K Buy
25,042
+5,025
+25% +$10.1K ﹤0.01% 4933
2024
Q4 		$36.6K Buy
20,017
+1,091
+6% +$4.83K ﹤0.01% 5161
2024
Q3 		$109K Buy
18,926
+13,218
+232% +$109K ﹤0.01% 4726
2024
Q2 		$46.1K Sell
5,708
-29,472
-84% -$310K ﹤0.01% 4626
2024
Q1 		$488K Buy
35,180
+35,171
+390,789% +$304K ﹤0.01% 3589
2023
Q4 		$57 Sell
9
-278
-97% -$1.37K ﹤0.01% 5580
2023
Q3 		$1.34K Sell
287
-118
-29% -$652 ﹤0.01% 5047
2023
Q2 		$2.17K Sell
405
-154,594
-100% -$1.25M ﹤0.01% 5280
2023
Q1 		$1.53M Buy
154,999
+56,663
+58% +$966K ﹤0.01% 2201
2022
Q4 		$1.84M Sell
98,336
-69,522
-41% -$1.58M ﹤0.01% 2104
2022
Q3 		$3.48M Buy
167,858
+39,538
+31% +$1.01M ﹤0.01% 1765
2022
Q2 		$2.66M Buy
128,320
+101,946
+387% +$2.87M ﹤0.01% 1910
2022
Q1 		$1.14M Sell
26,374
-37,520
-59% -$1.69M ﹤0.01% 2849
2021
Q4 		$3.83M Buy
63,894
+32,867
+106% +$2.63M ﹤0.01% 2056
2021
Q3 		$2.67M Sell
31,027
-20,627
-40% -$2.07M ﹤0.01% 2310
2021
Q2 		$5.75M Buy
51,654
+9,833
+24% +$944K ﹤0.01% 1785
2021
Q1 		$4.66M Buy
41,821
+31,773
+316% +$4.18M ﹤0.01% 1826
2020
Q4 		$1.07M Buy
10,048
+3,172
+46% +$422K ﹤0.01% 3482
2020
Q3 		$957K Sell
6,876
-15,967
-70% -$3.33M ﹤0.01% 3311
2020
Q2 		$7.39M Buy
22,843
+14,322
+168% +$2.3M 0.01% 1547
2020
Q1 		$761K Buy
8,521
+1,559
+22% +$96.1K ﹤0.01% 3452
2019
Q4 		$276K Buy
6,962
+1,807
+35% +$54.4K ﹤0.01% 4913
2019
Q3 		$127K Sell
5,155
-2,150
-29% -$65.4K ﹤0.01% 5501
2019
Q2 		$257K Buy
7,305
+1,216
+20% +$48.3K ﹤0.01% 5042
2019
Q1 		$273K Sell
6,089
-15,252
-71% -$769K ﹤0.01% 4794
2018
Q4 		$1.02M Buy
21,341
+4,923
+30% +$299K ﹤0.01% 3377
2018
Q3 		$1.09M Buy
16,418
+3,462
+27% +$193K ﹤0.01% 3399
2018
Q2 		$609K Sell
12,956
-3,187
-20% -$176K ﹤0.01% 3881
2018
Q1 		$912K Sell
16,143
-1,812
-10% -$98.1K ﹤0.01% 3329
2017
Q4 		$890K Buy
17,955
+4,895
+37% +$303K ﹤0.01% 3451
2017
Q3 		$994K Buy
13,060
+8,662
+197% +$645K ﹤0.01% 3384
2017
Q2 		$414K Buy
4,398
+683
+18% +$58.4K ﹤0.01% 4148
2017
Q1 		$295K Sell
3,715
-10,975
-75% -$874K ﹤0.01% 4323
2016
Q4 		$1.22M Buy
14,690
+8,279
+129% +$749K ﹤0.01% 3476
2016
Q3 		$717K Buy
6,411
+1,520
+31% +$168K ﹤0.01% 3567
2016
Q2 		$542K Sell
4,891
-4,468
-48% -$543K ﹤0.01% 3587
2016
Q1 		$978K Buy
9,359
+4,345
+87% +$335K ﹤0.01% 3372
2015
Q4 		$405K Sell
5,014
-5,653
-53% -$450K ﹤0.01% 4073
2015
Q3 		$740K Buy
10,667
+5,454
+105% +$475K ﹤0.01% 3364
2015
Q2 		$510K Sell
5,213
-266
-5% -$28.4K ﹤0.01% 3688
2015
Q1 		$536K Sell
5,479
-801
-13% -$77.6K ﹤0.01% 3676
2014
Q4 		$691K Buy
6,280
+930
+17% +$114K ﹤0.01% 3547
2014
Q3 		$632K Buy
5,350
+973
+22% +$121K ﹤0.01% 3361
2014
Q2 		$568K Sell
4,377
-2,239
-34% -$264K ﹤0.01% 3380
2014
Q1 		$1.06M Sell
6,616
-664
-9% -$95.3K ﹤0.01% 2829
2013
Q4 		$1.01M Buy
7,280
+416
+6% +$41.6K ﹤0.01% 3166
2013
Q3 		$682K Buy
6,864
+907
+15% +$76K ﹤0.01% 3202
2013
Q2 		$228K Buy
+5,957
New +$181K ﹤0.01% 4162

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citigroup's INO Position: Q4 2025 in Review

Citigroup sold out of Inovio Pharmaceuticals (INO) in Q4 2025, closing a stake of 12,977 shares — an estimated $30.4K sold.

Citigroup first reported a position in INO in Q2 2013 and held it in 50 quarters. The position peaked at $7.39M in Q2 2020. 102 funds tracked by Wall St. Rank hold INO as of Q4 2025.

  • Citigroup reported no remaining Inovio Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Citigroup sold 12,977 Inovio Pharmaceuticals shares in Q4 2025, an estimated $30.4K.
  • Citigroup first reported a position in Inovio Pharmaceuticals in Q2 2013 and held it in 50 quarters.
  • Citigroup's Inovio Pharmaceuticals position peaked at $7.39M in Q2 2020.
  • 102 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2025.

Based on Citigroup's 13F filing for Q4 2025, filed 13 Feb 2026.